TGLA

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTGLA

Drug Alias Nameanti-CD20 chimeric antibody (Chinese Academy of Sciences)TGLA

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesChinese Academy Of Sciences

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesChinese Academy Of Sciences

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A